Alnylam partners with Roche to develop RNAi therapeutic for hypertension
Alnylam Pharmaceuticals, an RNAi therapeutics company, has partnered with Roche to develop and commercialize zilebesiran.
Source: biopharma-reporter.com
Page 49 - Bio Developments News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bio Developments Today - Breaking & Trending Today
Gilead scraps phase 3 trial of blood cancer treatment
Gilead Sciences has decided to end a phase 3 trial of magrolimab for higher-risk myelodysplastic syndromes (MDS) after an analysis suggested it would be futile to continue.
Source: biopharma-reporter.com
PrecisionLife identifies genetic risk factors for long COVID
PrecisionLife, a computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Source: biopharma-reporter.com
Alnylam announces positive results for Alzheimer's treatment
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose portion of the phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).
Source: biopharma-reporter.com
Merck invests €23 million to expand cell culture media production
Science and technology company Merck has announced the expansion of its facility in Lenexa, Kansas, USA, adding 9,100 sq m2 of lab space and production capability to manufacture cell culture media.
Source: biopharma-reporter.com